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The aim of this paper was to evaluate the factors that predict regression of untreated CIN 2 and 3. A total of 93 patients with
colposcopic persistent CIN 2 and 3 lesions after biopsy were followed for 6 months. Human papillomavirus (HPV) types were
determined by polymerase chain reaction at enrolment. We analysed the biologic and demographic predictors of natural regression
using univariate and multivariate methods. The overall regression rate was 52% (48 out of 93), including 58% (22 out of 38) of CIN 2
and 47% (26 out of 55) of CIN 3 lesions (P¼0.31 for difference). Human papillomavirus was detected in 84% (78 out of 93) of
patients. In univariate analysis, 80% (12 out of 15) of lesions without HPV regressed compared to 46% (36 out of 78) of lesions with
HPV infection (P¼0.016). Women without HPV and those who had a resolution of HPV had a four-fold higher chance of regression
than those with persistent HPV (relative odds¼3.5, 95% CI¼1.4–8.6). Women with five or fewer lifetime sexual partners had
higher rates of regression than women with more than five partners (P¼0.003). In multivariate analysis, HPV status and number of
sexual partners remained as significant independent predictors of regression. In conclusion, HPV status and number of lifetime sexual
partners were strongly predictive of regression of untreated CIN 2 and 3.
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Cervical cancer continues to be the most deadly female cancer in
developing countries. (Ponten et al, 1995) The dramatic decrease
in mortality rates in Western countries is attributed to cervical
cancer screening. (Harlan et al, 1991) The successful implementa-
tion of these screening programmes is based on the underlying
model that cervical intraepithelial lesions (CIN) behave as
progressive stages of a biologic continuum towards the develop-
ment of invasive cervical cancer (Richart and Barron, 1969;
Campion et al, 1986).
Genital human papillomavirus (HPV) infection has been
established as the critical step in the development of most cervical
cancers (IARC, 1995). The cervical carcinogenesis model involves
HPV infection, intraepithelial neoplasia, and invasion. Human
papillomavirus infection is found in over 40% of young, sexually
active, college students (Ho et al, 1998). However, the incidence of
cervical cancer is uncommon compared to the lifetime cumulative
incidence of viral infection. Thus, there must be essential
biological mechanisms and associated risk factors other than
HPV infection that are responsible for the progression of precursor
lesions to invasive cervical cancer (Schiffman & Brinton, 1995).
The aetiology and risk factors involved with cervical carcino-
genesis are amenable to study as invasive cervical cancer typically
arises after many years from a morphologically defined precancer-
ous lesion. However, since untreated high-grade lesions can
progress to invasive cancer, most women with CIN 2 or 3 are
treated promptly. Accordingly, there are few reports on the natural
history of high-grade dysplasia. On the other hand, not all CIN
lesions progress to invasive cancer. In fact, spontaneous regression
of moderate dysplasia has been reported in up to 54% of women
(Nasiell et al, 1983, 1986). Since many early lesions regress without
treatment, the ability to predict which lesions will regress offers the
hope of avoiding treatment and its associated complications which
include: cervical stenosis, incompetence, bleeding, and infection
(Hillard et al, 1991; Herzog et al, 1995).
We evaluated the predictors for natural regression of untreated
CIN 2 and 3 such as age, race, parity, smoking history, oral
contraceptive (OCP) use, marital status, lesion grade, sexual
history, and HPV status on all our patients.
MATERIALS AND METHODS
We performed an ancillary study to a prospective, double-blinded,
randomized, placebo-controlled trial of b-carotene in the manage-
ment of women with untreated CIN 2 or 3. Predictors for natural
regression, which included age, race, parity, smoking history, OCP
use, marital status, lesion grade, sexual history, and HPV status
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University of California, Irvine, Medical Center, nearby clinics, and
colleges. Women greater than 17 years of age with biopsy-proven
CIN 2 and 3 were screened. Eligible patients had colposcopic
persistence of CIN 2 or 3 one month after initial biopsy and had a
negative endocervical curettage. Two pathologists agreed on the
cervical histologic diagnosis before enrolment. Based on the
guidelines of the Institutional Review Board at University of
California, Irvine, written consents were obtained from all patients.
Since many preinvasive changes can regress spontaneously, we
were initially interested in studying the factors that influenced the
natural regression of CIN in the placebo group of our trial.
However, we discovered that there was no significant difference in
regression rates between the b-carotene and placebo arms at the
end of the study (Keefe et al, 2001). Thus, we elected to look at
those factors that influenced CIN regression in all study
participants assuming that all patients who regressed did so
spontaneously.
Diagnosis of cervical dysplasia and surveillance
This was a 6-month ancillary study of a 2-year randomised,
controlled trial of b-carotene in the management of women with
untreated CIN 2 or 3. Over the 6 months, which comprised the
study period for this current report, the subjects were followed at
3-month intervals with testing that included cytology, presence of
HPV in cervical scrapings, and colposcopy. All patients underwent
colposcopically-directed biopsies and endocervical curettage
before treatment and at 6 months. The two study pathologists
reviewed all biopsies obtained at the 6-month end point.
Regression was defined as CIN 2 lesions reverting to normal or
CIN 3 lesions converting to CIN 1 or normal. We defined persistent
CIN 3 lesions as those that did not regress from the time of the
initial biopsy to the 6-month end point. All patients with persistent
CIN 3 or whose lesions progressed to CIN 3 at 6 months were taken
off of the 2-year study and treated by conventional means.
HPV analysis
We collected cervical scrapings from our patients for HPV analysis
at enrolment, 3 and 6 months following the initial diagnostic CIN
biopsy. Persistence and resolution of HPV infection was deter-
mined by comparing the analyses between the initial and 6-month
time points. We defined HPV resolution as those with a presence
of HPV DNA at initial entry and subsequently had undetectable
levels of any HPV DNA at the 6-month end point. Furthermore,
HPV persistence was defined as those with any HPV DNA both at
baseline and 6 months. Although we detected mixed HPV types in
a few patients, the majority of women had one HPV type at
baseline that persisted throughout the 6 months.
Polymerase chain reaction (PCR) method was used to determine
HPV genotype as described (Monk et al, 1994). DNA was first
amplified with b-globin primers to confirm that the DNA extracted
was intact and suitable for PCR. The DNA was then amplified with
MY09/MY11 consensus primers that detect about 25 mucosal HPV
types as well as type-specific primers for HPV 6, 16, and 18. The
type-specific products were transferred to nylon membranes for
hybridisation with
32P probes. MYO9/MY11 consensus products
were assigned genotypes by RFLP digestion (Bernard et al, 1994)
or if necessary sequenced. If no HPV DNA was detected with the
primary primer sets, the DNA was then amplified with an
additional consensus primer in the E1 gene (Gregoire et al,
1989) and the product sequenced.
Risk factor analysis
We analysed the age, race, parity, smoking history, OCP use,
marital status, lesion grade, sexual history, and HPV status on all
our patients. We assessed the impact of various epidemiological
risk factors on regression of CIN in all our patients using
univariate (w
2) and multivariate (logistic regression) analyses
performed with Statistical Analysis Systems. All P-values reported
are two-tailed.
RESULTS
From 1992 to 1996, 982 patients were screened for our study. We
enrolled 124 women into our trial of whom 111 were eligible to be
randomized to b-carotene or placebo. One hundred three patients
had colposcopic persistence of CIN 2 or 3 one month after their
initial biopsy. Ninety-three (90%) patients completed our ancillary
study and underwent a 6-month cervical biopsy. The 10 excluded
patients did not have a documented persistence of CIN 2 or 3 after
initial biopsy. The median age of our patients was 29 years (range
19–55). The majority (59%) presented with CIN 3 lesions and 41%
had CIN 2 disease. Approximately one-half (46/93) were Hispanic
and the others were either Caucasian (n¼45) or Asian (n¼2).
Fifty (54%) women were married or have been married in the past.
Twenty-four (26%) women have completed high school or college.
The median parity was one. Forty-two (45%) women had a history
of OCP use. Twenty-eight (30%) patients were smokers and nine of
these women were smoking more than one pack per day. Of the 75
women who completed the sexual history interview, 54 (72%)
women had their first sexual intercourse at 18 years or younger
(range: 11–30) with a median of two lifetime sexual partners
(range: 1–25). At enrolment, HPV infection was detected in 84%
(78 out of 93) of women and most patients had HPV types that
were considered high risk for progressing to cancer. The HPV
types at baseline included HPV type 16 (42%), type 33 (12%), type
18 (9%), type 31 (8%), type 52 (3%), type 53 (3%), type 35 (1%),
type 39 (1%), and mixed/others (22%). Types 16, 18, and 33 were
the most prevalent HPV types and 11 patients were infected with
multiple HPV types.
We analysed the regression rates of CIN 2 and 3 with respect to
various demographic and biological risk factors. The overall
regression rate was 52% (48 out of 93), including 58% (22 out of
38) of CIN 2 lesions and 47% (26 out of 55) of CIN 3 lesions
(P¼0.31 for difference between grades). Interestingly, 80% (12 out
of 15) of lesions without detectable levels of HPV regressed
compared to only 46% (36 out of 78) of those infected with HPV
(P¼0.016). Of the 78 patients who initially tested positive for
HPV, 24% (19 out of 78) subsequently developed undetectable
levels of HPV. Of the patients who had a resolution of their HPV
infection, 63% (12 out of 19) showed regression of their disease
compared to a regression rate of only 41% (24 out of 59) in those
who had a persistence of their viral infection. After the study, the
population was divided into two groups based on the number of
lifetime sexual partners: less than or equal to five and more than
five. There was a significant inverse relationship (P¼0.003)
between number of sexual partners and probability of CIN
regression (Table 1).
In univariate analyses, we found that absence of persistent HPV
infection (P¼0.005), less than or equal to five sexual partners
(P¼0.003), and Hispanic race (P¼0.05) were all significant
predictors for regression of high-grade dysplasia. Age, parity,
smoking history, OCP use, marital status, lesion grade, and age at
first intercourse were not significantly associated with CIN
regression (Table 1). To further examine the variables identified
as important in the univariate analyses, a multivariate logistic
regression analysis was performed. We confirmed that the absence
of HPV infection and less than or equal to five sexual partners
remained as significant independent predictors for CIN regression
(Table 2). After adjusting for HPV infection and number of sexual
partners, Hispanic race was no longer a significant predictor of
CIN regression. Inclusion of treatment group (b-carotene vs
Predictors for natural regression of CIN 2 and 3
JK Chan et al
1063
British Journal of Cancer (2003) 89(6), 1062–1066 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yplacebo) in the multivariate model did not change the estimates of
risk of regression associated with HPV infection or number of
sexual partners.
DISCUSSION
Over the last 30 years, it has been widely accepted that CIN 1, 2,
and 3 represent a continuum in the development of invasive
cervical cancer (Kiviat, 1996). The biology of the various CIN
grades vary, however, with the majority of CIN 1 lesions regressing
without treatment (Nasiell et al, 1986; Montz et al, 1992; Flannelly
et al, 1994), while CIN 2 and 3 lesions have a higher risk of
persisting or progressing to invasive cancer. (Luthra et al, 1987;
Murthy et al, 1996) Typically, most patients with CIN 2 or 3 lesions
are promptly treated with ablation of the lesion or conisation of
the cervix to prevent invasive disease. Consequently, studies on the
natural history of untreated CIN 2 or 3 are limited (Nasiell et al,
1983; Luthra et al, 1987; Syrjanen et al, 1992; Flannelly et al, 1994).
In addition, results from previous studies of the natural history of
CIN are difficult to interpret because many studies depended on
cytologic evaluation rather than histologic diagnosis to confirm
either diagnosis or regression of disease. Furthermore, there often
was a lack of uniform criteria in assigning a grade of dysplasia
among the studies (Ostor, 1993; Holowaty et al, 1999). Lastly,
repeat colposcopic examinations typically were not performed to
confirm the persistence of CIN after the diagnostic biopsy. This
lack of confirmation of persistent disease is important because
many cervical lesions may regress after the initial diagnostic
biopsy. All patients enrolled in our study had biopsy-proven and
persistent CIN 2 or 3 lesions. Colposcopic examinations were
performed 1 month after the initial biopsy to document disease
persistence. Moreover, two pathologists agreed on the histologic
diagnoses at the beginning and end of the study.
After all 93 patients were analysed in our study, we found that
the regression rate of CIN 2 and 3 without conventional therapy
was unexpectedly high at 52%. Regression included 58% of CIN 2
lesions and 47% of CIN 3 lesions. In contrast, Ostor’s (1993) 40-
year review of all reports that addressed the natural history of CIN
found that the regression rates of CIN 2 and 3 averaged only 43
and 32%, respectively. Unfortunately, some of these studies were
hampered by a failure to confirm persistent disease after initial
biopsy and inconsistent methods of determining grade of CIN. As
one of the few reports on biopsy-proven and persistent CIN 2 or 3
disease, we found that the regression rates of high-grade lesions
are unexpectedly high. These findings might influence the decision
to routinely manage all patients with high-grade dysplasia by
ablation, LEEP, or cone biopsy, particularly if undetectable levels
of HPV are present.
The presence of cervical HPV DNA often is associated with
cytologic and histologic changes of CIN. Indeed, up to 90%
of women with CIN are HPV DNA positive depending on the
diagnostic method used (Kiviat et al, 1992; Schiffman, 1992).
In our analysis, women who lacked detectable HPV by PCR
following the biopsy had a significantly greater chance of CIN
regression compared to those with persistent HPV infections.
This finding is consistent with previous studies that have shown
that persistent HPV infections enhance the development and
persistence of squamous intraepithelial lesions (Karlsson et al,
1995; Romney et al, 1997; Ho et al, 1998). Furthermore,
our patients who initially tested positive for HPV and subsequently
developed undetectable levels of HPV had higher rates of CIN
regression (63%) than patients with HPV persistence (41%).
Previous data have also shown that the resolution of HPV infection
reflects the natural regression patterns of squamous intraepithelial
lesions (Nasiell et al, 1986; Daling et al, 1996). Since most
HPV infections are transient (Rosenfeld et al, 1992; Hsing et al,
1994; Hinchliffe et al, 1995; Romney et al, 1997), the patients in
our study with high-grade lesions, who had no detectable HPV in
their cervical scrapings following the biopsy, may have had a
resolving HPV infection. Thus, based on our findings and that
of other investigations, it appears that the resolution of HPV
infection is predictive of the spontaneous regression of high-grade
lesions. This has strong implications for the role of antiviral
therapies against HPV and subsequent regression of high-grade
dysplasia. Unlike previous reports (Campion et al, 1986; Kataja
et al, 1990), our study did not find a significant difference in
regression rates between patients with high risk (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, and 58) and other HPV types. However, we
Table 1 Univariate analyses
Variable Regression rate
(%)
P-value for
difference
HPV status
Remained negative 80 (n¼15)
Resolved 63 (n¼19)
Persisted 41 (n¼59) 0.004
Number of sexual partners
p56 1
45 27 0.003
Race
Hispanic 61
White 40 0.05
Age (years)
p30 44
430 61 0.11
Parity
p24 6
42 64 0.11
Smoking (ever)
Yes 39
No 57 0.12
Lesion grade
CIN 2 58
CIN 3 47 0.31
Age at first intercourse (years)
o18 48
X18 57 0.48
Use of oral contraceptives (ever)
Yes 48
No 55 0.48
Marital status
Single 49
Ever-married 54 0.62
Table 2 Multivariate analysis
Variables Odds ratio 95% CI
HPV infection
No 3.3 (1.3–8.6)
Yes 1
Number of lifetime sexual partners
p5 4.1 (1.4–11.5)
451
CI¼confidence interval; HPV¼human papillomavirus.
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both low- and high-risk HPV types. Similarly, Ellerbrock et al
(2000) also found that persistent HPV infection with or without
type 16 or 18 was significantly associated with incident cervical
lesions.
The role of HPV infection provides only a partial explanation for
the high rate of spontaneous regression in our patient population.
Sexual risk factors also have been recognised as causative
determinants for CIN and cervical cancer. In our study, we found
an inverse relationship between the number of sexual partners and
CIN regression. Multivariate analyses of our study population
showed that the effects of sexual risk factors persist even after
controlling for HPV infections; suggesting that the presence of
other sexually transmitted disease may also play a role in the
natural history of CIN 2 or 3.
Our data propose that there may be selected patients with CIN
who could be followed for short term in anticipation of
spontaneous regression; this group includes those with no
evidence of an HPV infection and low sexual risk factors. Indeed,
the ASCUS-LSIL Triage Study reached this conclusion for patients
with ASCUS Pap smears in whom HPV is not present (Solomon
et al, 2001). Certainly, larger studies are needed to determine the
safety and efficacy of conservative treatment of CIN 2 or 3;
however, the short-term risk of progressing onto cancer in this
population is very low (Holowaty et al, 1999). It is possible that the
recommendation to observe women with ASCUS Pap smears who
are negative for HPV may be applicable as short-term recommen-
dations for women with established CIN, even when of high grade.
Lastly, clinical trials are needed to determine the role of anti-HPV
therapies including vaccines and immune modulators to prevent
or eliminate HPV infection and potentially enhance the regression
of CIN. With the high rate of spontaneous regression of CIN 2 and
3 in our patients, it may be safe and feasible to initiate a
prospective, randomised trial to further investigate the natural
regression of high-grade dysplasia.
ACKNOWLEDGEMENTS
We acknowledge Sandhya Upasani for her statistical support. This
work was financially supported by National Cancer Institute,
National Institutes of Health (NCI RO1-CA-50364).
REFERENCES
Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL,
Bauer HM, Wheeler CM (1994) Identification and assessment of
known and novel human papillomaviruses by polymerase chain
reaction amplification, restriction fragment length polymorphisms,
nucleotide sequence, and phylogenetic algorithms. J Infect Dis 170:
1077–1085
Campion MJ, McCance DJ, Cuzick J, Singer A (1986) Progressive potential
of mild cervical atypia: prospective cytological, colposcopic, and
virological study. Lancet 2: 237–240
Daling JR, Madeleine MM, McKnight B, Carter JJ, Wipf GC, Ashley R,
Schwartz SM, Beckmann AM, Hagensee ME, Mandelson MT, Galloway
DA (1996) The relationship of human papillomavirus-related cervical
tumors to cigarette smoking, oral contraceptive use, and prior herpes
simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev 5:
541–548
Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K,
Wright Jr TC (2000) Incidence of cervical squamous intraepithelial
lesions in HIV-infected women. JAMA 283: 1031–1037
Flannelly G, Anderson D, Kitchener HC, Mann EM, Campbell M, Fisher P,
Walker F, Templeton AA (1994) Management of women with mild and
moderate cervical dyskaryosis [see comments]. BMJ 308: 1399–1403
Gregoire L, Arella M, Campione-Piccardo J, Lancaster WD (1989)
Amplification of human papillomavirus DNA sequences by using
conserved primers. J Clin Microbiol 27: 2660–2665
Harlan LC, Bernstein AB, Kessler LG (1991) Cervical cancer screening: who
is not screened and why? Am J Public Health 81: 885–890
Herzog TJ, Williams S, Adler LM, Rader JS, Kubiniec RT, Camel HM,
Mutch DG (1995) Potential of cervical electrosurgical excision procedure
for diagnosis and treatment of cervical intraepithelial neoplasia. Gynecol
Oncol 57: 286–293
Hillard PA, Biro FM, Wildey L (1991) Complications of cervical
cryotherapy in adolescents. J Reprod Med 36: 711–716
Hinchliffe SA, van Velzen D, Korporaal H, Kok PL, Boon ME (1995)
Transience of cervical HPV infection in sexually active, young women
with normal cervicovaginal cytology. Br J Cancer 72: 943–945
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history
of cervicovaginal papillomavirus infection in young women. N Engl J
Med 338: 423–428
Holowaty P, Miller AB, Rohan T, To T (1999) Natural history of dysplasia of
the uterine cervix. J Natl Cancer Inst 91: 252–258
Hsing AW, Schiffman M, Zhang T, Greer CE, Chen CJ, You SL, Hsieh CY,
Huang TW, Liaw KL, Manos M (1994) Persistence of type-specific human
papillomavirus infection among cytologically normal women [letter;
comment]. J Infect Dis 170: 498
IARC (1995) IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans 64. Lyon, France: International Agency for Research on Cancer
Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E,
Rylander E, Wadell G (1995) Lifetime number of partners as the only
independent risk factor for human papillomavirus infection: a popula-
tion-based study. Sex Transm Dis 22: 119–127
Kataja V, Syrjanen K, Syrjanen S, Mantyjarvi R, Yliskoski M, Saarikoski S,
Salonen JT (1990) Prospective follow-up of genital HPV infections:
survival analysis of the HPV typing data. Eur J Epidemiol 6: 9–14
Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose
GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver
H, Meyskens FL, Berman ML (2001) A randomized, double blind, Phase
III trial using oral beta-carotene supplementation for women with high-
grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers
Prev 10: 1029–1035
Kiviat N (1996) Natural history of cervical neoplasia: overview and update.
Am J Obstet Gynecol 175: 1099–1104
Kiviat NB, Koutsky LA, Critchlow CW, Lorincz AT, Cullen AP, Brockway J,
Holmes KK (1992) Prevalence and cytologic manifestations of human
papilloma virus (HPV) types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52,
and 56 among 500 consecutive women. Int J Gynecol Pathol 11: 197–203
Luthra UK, Prabhakar AK, Seth P, Agarwal SS, Murthy NS, Bhatnagar P,
Das DK, Sharma BK (1987) Natural history of precancerous and early
cancerous lesions of the uterine cervix. Acta Cytol 31: 226–234
Monk BJ, Cook N, Ahn C, Vasilev SA, Berman ML, Wilczynski SP (1994)
Comparison of the polymerase chain reaction and Southern blot analysis
in detecting and typing human papilloma virus deoxyribonucleic acid in
tumors of the lower female genital tract. Diagn Mol Pathol 3: 283–291
Montz FJ, Monk BJ, Fowler JM, Nguyen L (1992) Natural history of the
minimally abnormal Papanicolaou smear. Obstet Gynecol 80: 385–388
Murthy NS, Sardana S, Narang N, Agarwal SS, Sharma S, Das DK (1996)
Biological behaviour of moderate dysplasia – a prospective study. Indian
J Cancer 33: 24–30
Nasiell K, Nasiell M, Vaclavinkova V (1983) Behavior of moderate cervical
dysplasia during long-term follow-up. Obstet Gynecol 61: 609–614
Nasiell K, Roger V, Nasiell M (1986) Behavior of mild cervical dysplasia
during long-term follow-up. Obstet Gynecol 67: 665–669
Ostor AG (1993) Natural history of cervical intraepithelial neoplasia: a
critical review. Int J Gynecol Pathol 12: 186–192
Ponten J, Adami HO, Bergstrom R, Dillner J, Friberg LG, Gustafsson L,
Miller AB, Parkin DM, Sparen P, Trichopoulos D (1995) Strategies for
global control of cervical cancer [see comments]. Int J Cancer 60: 1–26
Richart RM, Barron BA (1969) A follow-up study of patients with cervical
dysplasia. Am J Obstet Gynecol 105: 386–393
Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, Mikhail M,
Hagan RJ, Chang CJ, Burk RD (1997) Effects of beta-carotene and other
factors on outcome of cervical dysplasia and human papillomavirus
infection. Gynecol Oncol 65: 483–492
Predictors for natural regression of CIN 2 and 3
JK Chan et al
1065
British Journal of Cancer (2003) 89(6), 1062–1066 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yRosenfeld WD, Rose E, Vermund SH, Schreiber K, Burk RD (1992) Follow-
up evaluation of cervicovaginal human papillomavirus infection in
adolescents. J Pediatr 121: 307–311
Schiffman MH (1992) Recent progress in defining the epidemiology of
human papillomavirus infection and cervical neoplasia. J Natl Cancer
Inst 84: 394–398
Schiffman MH, Brinton LA (1995) The epidemiology of cervical
carcinogenesis. Cancer 76: 1888–1901
Solomon D, Schiffman M, Tarone R (2001) Comparison of three manage-
ment strategies for patients with atypical squamous cells of undeter-
mined significance: baseline results from a randomized trial. J Natl
Cancer Inst 93: 293–299
Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S (1992)
Natural history of cervical human papillomavirus lesions does not
substantiate the biologic relevance of the Bethesda System. Obstet
Gynecol 79: 675–682
Predictors for natural regression of CIN 2 and 3
JK Chan et al
1066
British Journal of Cancer (2003) 89(6), 1062–1066 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y